Brief: InflaRx Reports Q1 Results
May 11 (Reuters) - InflaRx NV IF0G.F :
* INFLARX REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING
RESULTS AND PROVIDES BUSINESS UPDATE
* INFLARX NV - CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES
APPROXIMATELY EUR 72.3 MILLION AS OF MARCH 31, 2023
* INFLARX NV - CURRENT FUNDS ON HAND ARE EXPECTED TO BE
SUFFICIENT
TO FUND OPERATIONS INTO 2026
* INFLARX NV - NET LOSS IN Q1 2023, AMOUNTED TO EUR 11.1
MILLION,
COMPARED TO EUR 14.0 MILLION IN Q1 2022
Source text for Eikon: ID:nGNX9LtDnD
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum